Osteoporosis: A pharmacotherapy update

Journal of Pharmacy Practice

Volumn 16, Issue 3, 2003, Pages 164-169

  Brown, Thomas E R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bisphosphonates; Hormone replacement therapy; Osteoporosis; Parathyroid hormone; Pharmacotherapy; Raloxifene

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; IPRIFLAVONE; MENATETRENONE; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; VITAMIN K GROUP; ZOLEDRONIC ACID;

BONE DENSITY; BONE MINERAL; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG RESPONSE; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONE SUBSTITUTION; HUMAN; LEG CRAMP; NAUSEA; OSSIFICATION; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; STANDARD; THROMBOEMBOLISM; VERTIGO;

EID: 0038778630     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190003016003004     Document Type: Review

References (28)

1. Papaioannou A, Watts NB, Kendler DL, Yuen CK, Adachi JD, Ferko, N. Diagnosis and management of vertebral fractures in elderly adults. Am J Med. 2002;113:220-228.
2. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med. 1991;151:2026-2032.
3. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(suppl 10):S1-S34.
4. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Executive summary. Osteoporosis Int. 1998;8(suppl 4):S3-S6.
5. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age: early postmenopausal intervention cohort study group. N Engl J Med. 1998;338:485-492.
6. The writing group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1996;276:1389-1396.
7. Lufkin EG, Wahner HW, O'Fallon WH, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
8. Writing group for the Women's Health Initiative investigators. Risks and benefit of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288:321-333.
9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
10. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclic etidronate therapy on bone mass and fracture in postmenopausal osteoporosis. N Engl J Med. 1990;322:1265-1271.
11. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclic etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73-79.
12. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporsis. N Engl J Med. 1995;333:1437-1443.
13. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture trial research intervention group. Lancet. 1996;348:1535-1541.
14. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA. 1999;282:1344-1352.
15. McClung MR, Geusens P, Miller PD, et al. The effects of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333-340.
16. Greenspan SL, Bone G III, Schnitzer TJ, et al. Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002;17:1988-1996.
17. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71:103-111.
18. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
19. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA. 2002;287:847-857.
20. Chestnut CH III, Silverman S, Andriano K, Genant HK, Gimona A, Harris S. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fracture Study. Am J Med. 2000;109:267-276.
21. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
22. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med. 1995;99:36-42.
23. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized controlled clinical trial. J Clin Endorcinol Metab. 1999;84:3076-81.
24. Harris ST, Eriksen EF, Davidson M, et al. Effect of risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001;86:1890-1897.
25. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene on bone mineral and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:985-992.
26. Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res. 2001;16:1871-1878.
27. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.
28. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab. 2002;87:2060-2066.